JP2022542443A5 - - Google Patents

Info

Publication number
JP2022542443A5
JP2022542443A5 JP2022506455A JP2022506455A JP2022542443A5 JP 2022542443 A5 JP2022542443 A5 JP 2022542443A5 JP 2022506455 A JP2022506455 A JP 2022506455A JP 2022506455 A JP2022506455 A JP 2022506455A JP 2022542443 A5 JP2022542443 A5 JP 2022542443A5
Authority
JP
Japan
Prior art keywords
domain
seq
bcma
amino acid
antigen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506455A
Other languages
English (en)
Japanese (ja)
Other versions
JP7729561B2 (ja
JP2022542443A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/071831 external-priority patent/WO2021023721A1/en
Publication of JP2022542443A publication Critical patent/JP2022542443A/ja
Publication of JP2022542443A5 publication Critical patent/JP2022542443A5/ja
Application granted granted Critical
Publication of JP7729561B2 publication Critical patent/JP7729561B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506455A 2019-08-02 2020-08-03 多発性骨髄腫治療用の抗bcma car t細胞 Active JP7729561B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382673.2 2019-08-02
EP19382673 2019-08-02
PCT/EP2020/071831 WO2021023721A1 (en) 2019-08-02 2020-08-03 Car t-cells against bcma for the treatment of multiple myeloma

Publications (3)

Publication Number Publication Date
JP2022542443A JP2022542443A (ja) 2022-10-03
JP2022542443A5 true JP2022542443A5 (cg-RX-API-DMAC7.html) 2023-08-14
JP7729561B2 JP7729561B2 (ja) 2025-08-26

Family

ID=67658496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506455A Active JP7729561B2 (ja) 2019-08-02 2020-08-03 多発性骨髄腫治療用の抗bcma car t細胞

Country Status (18)

Country Link
US (1) US12509525B2 (cg-RX-API-DMAC7.html)
EP (2) EP4272837A3 (cg-RX-API-DMAC7.html)
JP (1) JP7729561B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020325690A1 (cg-RX-API-DMAC7.html)
CA (1) CA3148930A1 (cg-RX-API-DMAC7.html)
DK (1) DK4007777T5 (cg-RX-API-DMAC7.html)
ES (1) ES2971033T3 (cg-RX-API-DMAC7.html)
FI (1) FI4007777T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240037T1 (cg-RX-API-DMAC7.html)
HU (1) HUE064890T2 (cg-RX-API-DMAC7.html)
LT (1) LT4007777T (cg-RX-API-DMAC7.html)
PL (1) PL4007777T3 (cg-RX-API-DMAC7.html)
PT (1) PT4007777T (cg-RX-API-DMAC7.html)
RS (1) RS65094B1 (cg-RX-API-DMAC7.html)
SI (1) SI4007777T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400013T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021023721A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201166B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4475896A1 (en) * 2022-02-09 2024-12-18 Hadasit Medical Research Services&Development Ltd. Anti-bcma car to target immune-related disorders, compositions and method thereof
EP4378953A1 (en) * 2022-12-02 2024-06-05 Universitat de Barcelona Cd229 targeting moiety for the tratment of cd229 positive cancer
WO2025141187A1 (en) * 2023-12-29 2025-07-03 Fundación Para La Investigación Biomédica Del Hospital Universitario 12 De Octubre T cells expressing anti-bcma/anti-cd3 bispecific antibodies and uses thereof
CN122140960B (zh) * 2026-05-11 2026-08-11 重庆医科大学附属第一医院 一种双适配体修饰的膜融合脂质体及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU6827094A (en) 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
NO3051026T3 (cg-RX-API-DMAC7.html) 2011-10-21 2018-07-28
EP2914628A1 (en) * 2012-11-01 2015-09-09 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
ES2546743B1 (es) 2014-03-28 2016-07-07 Institut D'investigació Biomèdica De Bellvitge (Idibell) Marcadores mitocondriales de enfermedades neurodegenerativas
BR112016024546A2 (pt) 2014-04-30 2018-01-23 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
US12048718B2 (en) * 2016-06-07 2024-07-30 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Geminschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
CN108004259B (zh) * 2016-11-02 2020-06-30 上海恒润达生生物科技有限公司 靶向b细胞成熟抗原的嵌合抗原受体及其用途
CN108285489A (zh) * 2017-01-09 2018-07-17 上海恒润达生生物科技有限公司 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途
CN108395478A (zh) * 2017-02-04 2018-08-14 上海恒润达生生物科技有限公司 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
AU2019233613B2 (en) 2018-03-13 2025-02-13 Sepsia Therapeutics, S.L. Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes

Similar Documents

Publication Publication Date Title
JP2020096630A5 (cg-RX-API-DMAC7.html)
JP2022061992A5 (cg-RX-API-DMAC7.html)
JP2021511807A5 (cg-RX-API-DMAC7.html)
JP2025165962A5 (cg-RX-API-DMAC7.html)
JP2022115932A5 (cg-RX-API-DMAC7.html)
JP2023514407A5 (cg-RX-API-DMAC7.html)
JP2016538830A5 (cg-RX-API-DMAC7.html)
JP2022531911A5 (cg-RX-API-DMAC7.html)
JP2019527543A5 (cg-RX-API-DMAC7.html)
JP2019511212A5 (cg-RX-API-DMAC7.html)
JP2022512882A5 (cg-RX-API-DMAC7.html)
HK1259190A1 (zh) 嵌合抗原受体相关的方法和组合物
JP2018523484A5 (cg-RX-API-DMAC7.html)
AU2016382512A1 (en) Immune effector cell therapies with enhanced efficacy
JP2018518540A5 (cg-RX-API-DMAC7.html)
JP2019527696A5 (cg-RX-API-DMAC7.html)
JP2010511388A5 (cg-RX-API-DMAC7.html)
JP2004501631A5 (cg-RX-API-DMAC7.html)
JP2018531014A5 (cg-RX-API-DMAC7.html)
JP2015501814A5 (cg-RX-API-DMAC7.html)
JP2016537966A5 (cg-RX-API-DMAC7.html)
CA2798390A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
JP2017500869A5 (cg-RX-API-DMAC7.html)
IL312602A (en) Bcma-targeted car-t cell therapy for multiple myeloma
JP2014502955A5 (cg-RX-API-DMAC7.html)